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BACKGROUND
Interferon-free regimens would be a major advance in the treatment of patients 
with chronic hepatitis C virus (HCV) infection.
METHODS
In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) 
and deleobuvir (a nonnucleoside polymerase inhibitor), we randomly assigned 362 
previously untreated patients with HCV genotype 1 infection to one of five groups: 
faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three 
times daily, plus ribavirin, for 16, 28, or 40 weeks (TID16W, TID28W, or TID40W, 
respectively); faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 
600 mg twice daily, plus ribavirin, for 28 weeks (BID28W); or faldaprevir at a dose 
of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, without 
ribavirin, for 28 weeks (TID28W-NR). The primary end point was a sustained viro-
logic response 12 weeks after the completion of therapy.
RESULTS
The primary end point was met in 59% of patients in the TID16W group, 59% of 
patients in the TID28W group, 52% of patients in the TID40W group, 69% of pa-
tients in the BID28W group, and 39% of patients in the TID28W-NR group. The 
sustained virologic response 12 weeks after the completion of therapy did not differ 
significantly according to treatment duration or dosage among ribavirin-contain-
ing regimens. This response was significantly higher with TID28W than with 
TID28W-NR (P = 0.03). Rates of a sustained virologic response 12 weeks after the 
completion of therapy were 56 to 85% among patients with genotype 1b infection 
versus 11 to 47% among patients with genotype 1a infection and 58 to 84% among 
patients with IL28B CC versus 33 to 64% with non-CC genotypes. Rash, photosen-
sitivity, nausea, vomiting, and diarrhea were the most common adverse events.
CONCLUSIONS
The rate of a sustained virologic response 12 weeks after the completion of therapy 
was 52 to 69% among patients who received interferon-free treatment with falda-
previr in combination with deleobuvir plus ribavirin. (Funded by Boehringer Ingel-
heim; SOUND-C2 ClinicalTrials.gov number, NCT01132313.)
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The introduction of the direct- acting antiviral agents telaprevir and boce-previr (nonstructural protein 3/4A [NS3/4A] 
protease inhibitors) was a major advance in the 
management of chronic infection with hepatitis C 
virus (HCV) genotype 1, the most prevalent and 
difficult-to-cure genotype.1 However, these drugs 
are used in combination with pegylated interfer-
on alfa and ribavirin, which are associated with a 
high rate of side effects and discontinuation.2 In 
addition, many patients cannot receive pegylated 
interferon because of contraindications.3
Host genetic factors are known to influence 
the response to treatment with pegylated inter-
feron and ribavirin in patients infected with 
HCV genotype 1. Single-nucleotide polymor-
phisms in the promoter region of the IL28B 
gene result in three genotypes: CC, CT, and TT 
(rs12879860), and patients with the CT or TT 
genotype have a reduced response to interferon-
based therapies.4 The influence of this host fac-
tor on a sustained virologic response in patients 
treated with interferon-free regimens is unknown.
Monotherapy with direct-acting antiviral agents 
is associated with rapid selection of viral variants 
that are resistant to the antiviral compound.4-7 
However, combinations of potent direct-acting 
antiviral agents targeting different stages of the 
HCV life cycle offer the possibility of interferon-
free treatment. The results of phase 1 and 2 
studies involving patients with HCV genotype 1 
infection have been encouraging and provide 
support for further development of combination 
therapies.8-13 In the phase 1b Safety and Anti-
viral Effect of Oral Combinations without Inter-
feron in Patients Diagnosed with Hepatitis C 
(SOUND-C1) study, patients who had not previ-
ously been treated for HCV infection received 
4 weeks of treatment with faldaprevir (an NS3/4A 
protease inhibitor) and deleobuvir (formerly known 
as BI207127; a nonnucleoside inhibitor of non-
structural protein 5B [NS5B] polymerase) plus 
ribavirin. At week 4, 100% and 73% of patients 
who received faldaprevir plus ribavirin with 600 
mg or 400 mg of deleobuvir, respectively, had 
HCV RNA levels that were lower than 25 IU per 
milliliter.12 Here we describe the phase 2b 
SOUND-C2 study, which assessed the efficacy 
and safety of the interferon-free combination of 
faldaprevir plus deleobuvir, with or without 
ribavirin, for 16, 28, or 40 weeks.
Me thods
Patients
Patients were enrolled at 48 sites in Europe, Aus-
tralia, and New Zealand. Eligible patients were 
18 to 75 years of age, had chronic HCV genotype 1 
infection (HCV RNA level ≥10,000 IU per milli-
liter), had compensated liver disease, and had not 
received treatment. Patients could have cirrhosis, 
which was determined either by means of biopsy 
(Metavir stage F4 on a scale from F0 to F4, with 
higher stages indicating a greater degree of fi-
brosis) or by means of transient elastography. 
The study protocol is available with the full text 
of this article at NEJM.org.
Study Design
The trial was a multicenter, randomized, open-
label, phase 2b study. Although no formal hypoth-
eses were stated, the study was designed to inves-
tigate the effect of treatment duration, deleobuvir 
dosage, and the absence or presence of ribavirin 
in treatment regimens on the virologic response. 
Patients were stratified at randomization accord-
ing to viral subtype (1a or 1b, which was deter-
mined by means of the Trugene HCV genotyping 
assay [Bayer] or the Versant HCV Genotype 2.0 
Assay [Siemens], if the Trugene result was incon-
clusive) and according to the IL28B (rs12979860) 
genotype (either CC or non-CC, which was deter-
mined by means of polymerase-chain-reaction 
TaqMan allelic discrimination assays14 [Applied 
Biosystems]). With the use of an interactive voice-
response system, the patients were assigned in a 
1:1:1:1:1 ratio to one of five treatment groups: 
faldaprevir at a dose of 120 mg once daily and 
deleobuvir at a dose of 600 mg three times daily, 
plus ribavirin, for 16 weeks (the TID16W group), 
28 weeks (TID28W), or 40 weeks (TID40W); 
faldaprevir at a dose of 120 mg once daily and 
deleobuvir at a dose of 600 mg twice daily, plus 
ribavirin, for 28 weeks (BID28W); and faldaprevir 
at a dose of 120 mg once daily and deleobuvir at 
a dose of 600 mg three times daily, without riba-
virin, for 28 weeks (TID28W-NR).
For the first dose of the study drugs, patients 
received a 1200-mg dose of deleobuvir (i.e., an 
additional 600-mg dose) and a 240-mg dose of 
faldaprevir (i.e., an additional 120-mg dose). The 
ribavirin dose was 1000 mg per day (for patients 
with a body weight of <75 kg) or 1200 mg per 
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day (for those with a body weight ≥75 kg). Step-
wise temporary reductions of the ribavirin dose 
and the use of erythropoietin were permitted to 
manage anemia.
Patients who had virologic breakthrough 
or a detectable level of HCV RNA at weeks 6 
and 8 were switched to pegylated interferon 
plus ribavirin and were considered to have had 
treatment failure. Breakthrough was defined as 
a confirmed increase in the HCV RNA level in 
two consecutive measurements to 25 IU per 
milliliter or higher for patients with HCV RNA 
levels that were previously lower than 25 IU per 
milliliter or 1 log10 IU per milliliter or higher 
for those with HCV RNA levels that were pre-
viously 25 IU per milliliter or higher. Relapse 
was defined as an HCV RNA level that was 
higher than 25 IU per milliliter after an unde-
tectable level of HCV RNA at the end of planned 
 treatment.
In a protocol amendment that was effective 
as of December 2011 (2 months before the inter-
nal database was unblinded), the definition of a 
sustained virologic response was changed from 
an undetectable level of HCV RNA 24 weeks after 
completion of therapy to an undetectable level 
of HCV RNA 12 weeks after completion of ther-
apy. This change was made on the basis of a 
meta-analysis of HCV clinical trials showing 
that a sustained virologic response 12 weeks 
after the completion of therapy had a positive 
predictive value of 98% for a sustained virologic 
response 24 weeks after the completion of ther-
apy.15 Other protocol amendments are described 
in the study protocol.
Study Oversight
The study was approved by the ethics committee 
at each participating site and was carried out in 
accordance with the Declaration of Helsinki and 
the International Conference on Harmonisation 
Guidelines for Good Clinical Practice. All patients 
provided written informed consent before en-
rollment.
The sponsor, Boehringer Ingelheim, designed 
and conducted the study in collaboration with 
the academic investigators. The sponsor moni-
tored the study, collected data, and performed 
the statistical analysis. The academic investigators, 
participating institutions, and sponsor agreed 
to maintain confidentiality of the data. The first 
draft of the manuscript was prepared by the first 
author with support from a medical writer em-
ployed by the sponsor, and the first author made 
the decision to submit the manuscript for publi-
cation. All the authors had access to the data 
and assume responsibility for the integrity and 
completeness of the data and for the fidelity of 
this report to the study protocol.
Efficacy Assessments
The primary efficacy end point was a sustained 
virologic response (i.e., undetectable level of HCV 
RNA) 12 weeks after the completion of therapy. 
The secondary efficacy end points were the time 
to an undetectable level of HCV RNA, an unde-
tectable level of HCV RNA at week 4 of treat-
ment, and an undetectable level of HCV RNA 24 
weeks after the completion of therapy.
Plasma HCV RNA levels were measured with 
the use of the quantitative COBAS TaqMan HCV 
High Pure System assay, version 2 (Roche), with 
a lower limit of quantification of 25 IU per milli-
liter and a lower limit of detection of 17 IU per 
milliliter. During treatment, HCV RNA levels 
were measured on days 1 and 4; at weeks 1, 2, 
4, 6, and 8; and every 4 weeks thereafter. After 
the end of the treatment period, HCV RNA levels 
were measured at 4, 8, 12, and 24 weeks.
Safety Assessments
Biochemical and hematologic assessments were 
performed at each visit during the treatment pe-
riod and 4 weeks after the last dose of the study 
drug was administered. Data on adverse events 
were obtained at each treatment visit and at the 
follow-up assessment. Physical examinations were 
performed at the screening visit, at the safety 
follow-up assessment, and as needed for the as-
sessment and treatment of symptoms during 
treatment visits. An independent data and safety 
monitoring committee conducted regular planned 
reviews of the safety data.
Drug-Resistance Assessments
Plasma samples from all visits at which levels of 
HCV RNA were measured were stored for moni-
toring of drug resistance. HCV nonstructural 
protein 3 (NS3) and NS5B regions were sequenced 
in all patients at baseline and in patients who 
had virologic breakthrough during treatment or 
relapse of infection in order to identify viral 
 variants associated with resistance to NS3/4A or 
NS5B inhibitors.
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Statistical Analysis
The primary efficacy and safety analyses were 
based on the intention-to-treat population (all 
randomly assigned patients who received at least 
one dose of study medication). The proportion of 
patients with a sustained virologic response 12 
weeks after the completion of therapy was calcu-
lated and compared among treatment groups 
with the use of a stratified Cochran–Mantel–
Haenszel test to adjust for HCV and IL28B geno-
types.16 Prespecified pairwise comparisons were 
made among the groups that received deleobuvir 
three times daily (to assess duration), between 
the BID28W and TID28W groups (to assess the 
deleobuvir dosage), and between the TID28W and 
TID28W-NR groups (to assess the effect of riba-
virin). Post hoc pairwise comparisons of rates of 
a sustained virologic response 12 weeks after the 
completion of therapy were calculated within 
each treatment group for genotype 1a versus 1b 
(with adjustment for the IL28B genotype) and for 
IL28B CC versus non-CC (with adjustment for the 
HCV genotype 1 subtype). All P values reported 
for statistical comparisons are for descriptive pur-
poses only; no significance threshold was pre-
specified, and no adjustments for multiple com-
parisons were performed. Ten post hoc subgroup 
comparisons were performed (the genotype 1 
subtype and IL28B genotype within treatment 
groups). If there were no true differences be-
tween subgroups at a 0.05 significance level, the 
chance of at least one false positive result would 
be approximately 40%.
We also performed a multivariate logistic-
regression analysis to evaluate the effects of 
covariates (age, sex, body-mass index, presence or 
absence of cirrhosis or diabetes, baseline alanine 
aminotransferase and γ-glutamyl transferase lev-
els, viral subtype, IL28B genotype, and baseline 
HCV RNA level) on virologic response rates. This 
analysis was based on the per-protocol popula-
tion, which excluded patients who prematurely 
discontinued the study therapy for reasons other 
than lack of efficacy (i.e., they had adverse 
events leading to discontinuation, were lost to 
follow-up, or withdrew consent).
R esult s
Patients
Of 469 patients who were screened, 362 under-
went randomization and received at least one 
dose of the study drugs (Fig. S1 in the Supple-
mentary Appendix, available at NEJM.org). En-
rollment in the TID28W-NR group was discon-
tinued on February 3, 2011, at the request of the 
Food and Drug Administration after other stud-
ies showed that virologic breakthrough was more 
common with interferon-free regimens that did 
not contain ribavirin than with those that did.13,17 
Baseline demographic and clinical characteristics 
were similar in the five study groups (Table 1).
Efficacy
Virologic response rates are shown in Table 2 
and in Table S1 in the Supplementary Appendix. 
There were no significant differences among 
rates of a sustained virologic response 12 weeks 
after the completion of therapy according to 
treatment duration (59% in the TID16W group 
vs. 59% in the TID28W group, P = 0.86; 59% in 
the TID16W group vs. 52% in the TID40W group, 
P = 0.37; and 59% in the TID28W group vs. 52% 
in the TID40W group, P = 0.46) or deleobuvir 
dosage (69% in the BID28W group vs. 59% in the 
TID28W group, P = 0.15). Rates of a sustained vi-
rologic response 12 weeks after the completion 
of therapy were higher among patients who re-
ceived ribavirin than among those who received 
the same regimen without ribavirin (59% in the 
TID28W group vs. 39% in the TID28W-NR group, 
P = 0.03).
Rates of a sustained virologic response 12 weeks 
after the completion of therapy were higher among 
patients with HCV genotype 1b infection than 
among those with HCV genotype 1a infection, 
after adjustment for IL28B genotype, in all groups 
except the TID40W group (BID28W, P<0.001; 
TID16W and TID28W-NR, P = 0.001; TID28W, 
P = 0.03; and TID40W, P = 0.38). Response rates 
were also higher among patients with the IL28B 
CC genotype than among patients with non-CC 
genotypes in the BID28W and TID28W-NR groups 
(P = 0.05 and P = 0.02, respectively) after adjustment 
for viral subtype.
Genotype 1b, IL28B CC genotype, female sex, 
treatment regimens containing ribavirin, and 
normal baseline γ-glutamyl transferase levels 
were associated with a higher rate of sustained 
virologic response 12 weeks after the completion 
of therapy in the multivariate analysis (Table S2 
in the Supplementary Appendix).
Fifty of the 75 patients who had virologic 
breakthrough during the study had HCV geno-
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type 1a infection. Relapse occurred in 19%, 2%, 
2%, 0%, and 10% of patients in the TID16W, 
TID28W, TID40W, BID28W, and TID28W-NR 
groups, respectively. Nine of 11 patients with 
relapsed infection in the TID16W group had 
HCV genotype 1a infection (Table 2).
A total of 97% of patients with virologic 
breakthrough (73 of 75 patients) had variants 
that emerged with mutants in both NS3 and 
NS5B, whereas the variants from patients who 
had relapsed infection were most commonly 
associated with single mutants in NS3 or NS5B 
(Table S3 in the Supplementary Appendix).
Safety
The most common adverse events were nausea, 
diarrhea, vomiting, jaundice, pruritus, rash, pho-
tosensitivity reaction, dry skin, asthenia, and fa-
tigue (Table 3). Across all groups, 340 patients 
(94%) had adverse events and 34 (9%) had severe 
adverse events (defined as events that were inca-
pacitating or led to an inability to work or per-
form usual activities). Between 56 and 73% of all 
the episodes of vomiting in the five treatment 
groups occurred during the first week of treat-
ment. A similar pattern was observed for other 
gastrointestinal adverse events. Rashes were gen-
erally maculopapular and were typical of drug-
related rashes. Photosensitivity reactions were 
commonly reported as exaggerated sunburns. 
Serious adverse events (defined as events that re-
sulted in death, were life-threatening, resulted in 
persistent or clinically significant disability or 
incapacity, required or prolonged hospitaliza-
tion, or were deemed to be serious by the investi-
gator for any other reason, as detailed in the pro-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
TID16W
(N = 81)
TID28W
(N = 80)
TID40W
(N = 77)
BID28W
(N = 78)
TID28W-NR
(N = 46)
Male sex — no. (%) 45 (56) 41 (51) 36 (47) 41 (53) 24 (52)
Race — no. (%)†
White 79 (98) 78 (98) 76 (99) 77 (99) 46 (100)
Black 2 (2) 1 (1) 0 1 (1) 0
Asian 0 1 (1) 0 0 0
Other 0 0 1 (1) 0 0
Age — yr 48.6±11.33 47.3±11.21 48.9±10.68 47.9±11.14 45.3±12.96
Body-mass index‡ 25.3±4.12 25.5±4.13 24.8±3.78 25.0±3.60 25.5±3.81
Cirrhosis — no. (%)§ 9 (11) 7 (9) 5 (6) 9 (12) 3 (7)
IL28B SNP rs12879860 genotype — no. (%)¶
CC 21 (26) 21 (26) 19 (25) 19 (24) 12 (26)
Non-CC‖║ 60 (74) 58 (72) 58 (75) 59 (76) 33 (72)
HCV genotype 1 subtype — no. (%)
1a 34 (42) 32 (40) 34 (44) 30 (38) 18 (39)
1b 47 (58) 48 (60) 43 (56) 48 (62) 28 (61)
HCV RNA ≥800,000 IU/ml — no. (%) 70 (86) 66 (82) 67 (87) 66 (85) 36 (78)
* The treatment regimens were as follows: faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg 
three times daily, plus ribavirin, for 16, 28, or 40 weeks (TID16W, TID28W, and TID40W, respectively); faldaprevir at a 
dose of 120 mg once daily and deleobuvir at a dose of 600 mg twice daily, plus ribavirin, for 28 weeks (BID28W); and 
faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, without ribavirin, for 
28 weeks (TID28W-NR). Plus–minus values are means ±SD. There were no significant differences among the treatment 
groups for any characteristic (P>0.10 for all comparisons). SNP denotes single-nucleotide polymorphism.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Cirrhosis was diagnosed by means of liver biopsy (Metavir stage F4 on a scale from F0 to F4, with higher stages indi-
cating a greater degree of fibrosis) or transient elastography (results of elastography were determined at the discretion 
of the investigator).
¶ Data on IL28B (rs12879860) were missing for one patient in the TID28W group and one patient in the TID28W-NR 
group.
‖ Overall, 21% of patients with non-CC genotypes had a TT genotype and 79% had a CT genotype.
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tocol) occurred in 7% of all patients (27 of 362). 
Of the patients with the most frequently reported 
events categorized as serious, 7 patients had skin 
disorders, 3 had infections, and 2 had anemia 
(Table S4 in the Supplementary Appendix).
The mean reductions in hemoglobin levels 
were 1.0 g per deciliter in the TID28W-NR group 
and approximately 2.5 g per deciliter in all other 
groups (Table 4). Anemia was reported as an 
adverse event in up to 13% of patients in the 
groups that received ribavirin and was not re-
ported in any of the patients in the TID28W-NR 
group. Mean platelet levels increased from base-
line during treatment in all groups (Table 4).
Table 2. Virologic Response during and after the Treatment Period.*
Variable
TID16W
(N = 81)
TID28W
(N = 80)
TID40W
(N = 77)
BID28W
(N = 78)
TID28W-NR
(N = 46)
number/total number (percent)
Undetectable HCV RNA 12 wk after com-
pletion of therapy: sustained 
 virologic  response
All patients 48/81 (59) 47/80 (59) 40/77 (52) 54/78 (69) 18/46 (39)
Patients with genotype 1a 13/34 (38) 14/32 (44) 16/34 (47) 13/30 (43) 2/18 (11)
Patients with genotype 1b 35/47 (74) 33/48 (69) 24/43 (56) 41/48 (85) 16/28 (57)
Patients with IL28B CC 14/21 (67) 14/21 (67) 12/19 (63) 16/19 (84) 7/12 (58)
Patients with IL28B non-CC 34/60 (57) 32/58 (55) 28/58 (48) 38/59 (64) 11/33 (33)
Reason for lack of a sustained virologic 
response
Futility criterion met†
All patients 3/81 (4) 4/80 (5) 0/77 1/78 (1) 2/46 (4)
Patients with genotype 1a 2/34 (6) 4/32 (12) 0/34 1/30 (3) 2/18 (11)
Patients with genotype 1b 1/47 (2) 0/48 0/43 0/48 0/28
Virologic breakthrough‡
All patients 9/81 (11) 14/80 (18) 15/77 (19) 18/78 (23) 19/46 (41)
Patients with genotype 1a 8/34 (24) 11/32 (34) 7/34 (21) 14/30 (47) 10/18 (56)
Patients with genotype 1b 1/47 (2) 3/48 (6) 8/43 (19) 4/48 (8) 9/28 (32)
Relapse§
All patients 11/59 (19) 1/50 (2) 1/42 (2) 0/54 2/21 (10)
Patients with genotype 1a 9/22 (41) 0/15 1/17 (6) 0/13 1/4 (25)
Patients with genotype 1b 2/37 (5) 1/35 (3) 0/25 0/41 1/17 (6)
Premature discontinuation¶ 8/81 (10) 12/80 (15) 19/77 (25) 3/78 (4) 5/46 (11)
Other reason‖ 2/81 (2) 2/80 (2) 2/77 (3) 2/78 (3) 0/46
* The HCV genotype 1 subtype was ascertained by means of sequencing analysis of the nonstructural 3/4A (NS3/4A) and 
5B (NS5B) genes. In 21 patients (6%), there were discrepancies between the genotype 1 subtype determined by means 
of the Trugene or Versant genotyping method and NS3/4A and NS5B sequencing. Six patients classified as having sub-
type 1a at screening were reclassified as having subtype 1b on sequencing of NS3/4A and NS5B, and 15 patients classi-
fied as having subtype 1b at screening were reclassified as having subtype 1a on sequencing of NS3/4A and NS5B.
† The criterion for futility was a detectable level of HCV RNA at weeks 6 and 8. Patients who met this criterion were 
switched to pegylated interferon and ribavirin.
‡ Virologic breakthrough was defined as either a confirmed increase in the HCV RNA level to 25 IU per milliliter or higher, 
for patients with HCV RNA levels that were previously lower than 25 IU per milliliter, or 1 log10 IU per milliliter or higher, 
for those with levels that were previously 25 IU per milliliter or higher.
§ Values shown are for patients who had an undetectable level of HCV RNA at the end of the assigned treatment.
¶ This category includes all patients who discontinued treatment for reasons other than a lack of efficacy (i.e., they had 
adverse events leading to discontinuation, were lost to follow-up, or withdrew consent).
‖ This category includes patients with missing data on a sustained virologic response 12 weeks after the completion of therapy 
and patients who had a detectable level of HCV RNA at the end-of-treatment visit and a detectable level of HCV RNA 
12 weeks after the completion of therapy.
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Table 3. Incidence and Severity of Common Adverse Events and Adverse Events Leading to Discontinuation of the Study Drugs.*
Variable TID16W (N = 81) TID28W (N = 80) TID40W (N = 77) BID28W (N = 78) TID28W-NR (N = 46)
number (percent)
Adverse events
Any adverse event 78 (96) 71 (89) 74 (96) 73 (94) 44 (96)
Mild adverse event† 50 (62) 31 (39) 28 (36) 36 (46) 22 (48)
Nausea‡ 39 (48) 32 (40) 36 (47) 33 (42) 24 (52)
Diarrhea 33 (41) 29 (36) 33 (43) 25 (32) 10 (22)
Vomiting 19 (23) 19 (24) 17 (22) 17 (22) 10 (22)
Jaundice§ 23 (28) 16 (20) 12 (16) 14 (18) 2 (4)
Pruritus 14 (17) 21 (26) 29 (38) 21 (27) 13 (28)
Rash¶ 18 (22) 12 (15) 25 (32) 17 (22) 9 (20)
Photosensitivity reaction‖ 22 (27) 22 (28) 19 (25) 23 (29) 15 (33)
Dry skin 11 (14) 10 (12) 11 (14) 17 (22) 6 (13)
Asthenia** 18 (22) 18 (22) 9 (12) 12 (15) 7 (15)
Fatigue 16 (20) 13 (16) 13 (17) 18 (23) 5 (11)
Moderate adverse event†† 27 (33) 32 (40) 34 (44) 28 (36) 18 (39)
Nausea‡ 2 (2) 10 (12) 5 (6) 6 (8) 2 (4)
Vomiting 4 (5) 10 (12) 3 (4) 3 (4) 2 (4)
Asthenia** 6 (7) 10 (12) 15 (19) 8 (10) 0
Fatigue 2 (2) 1 (1) 8 (10) 3 (4) 2 (4)
Rash¶ 4 (5) 2 (2) 2 (3) 0 7 (15)
Severe adverse event‡‡ 1 (1) 8 (10) 12 (16) 9 (12) 4 (9)
Anemia 0 1 (1) 0 1 (1) 0
Dehydration 0 1 (1) 0 1 (1) 0
Vomiting 0 0 4 (5) 0 1 (2)
Rash¶ 1 (1) 1 (1) 3 (4) 0 1 (2)
Photosensitivity reaction‖ 0 1 (1) 2 (3) 0 0
Asthenia** 0 0 1 (1) 2 (3) 0
Events leading to discontinuation 4 (5) 10 (12) 19 (25) 6 (8) 5 (11)
Nausea‡ 0 1 (1) 1 (1) 0 0
Vomiting 1 (1) 2 (2) 5 (6) 0 0
Diarrhea 0 0 2 (3) 1 (1) 0
Jaundice§§ 1 (1) 1 (1) 2 (3) 0 0
Photosensitivity reaction‖ 2 (2) 0 4 (5) 0 0
Rash¶,¶¶ 2 (2) 3 (4) 5 (6) 0 4 (9)
Asthenia** 0 0 6 (8) 0 0
Fatigue 0 1 (1) 2 (3) 0 0
* Definitions of adverse events are from the Medical Dictionary for Regulatory Activities, version 15. Adverse events were reported to be mild if 
they were transient in nature and generally did not interfere with usual activities, moderate if they were sufficiently discomforting to interfere 
with usual activities, and severe if they prevented usual activities.
† Listed are mild adverse events that occurred in at least 20% of patients in any treatment group during the treatment period.
‡ This category includes nausea with or without vomiting.
§ Jaundice of any severity was observed in 31%, 28%, 19%, 21%, and 4% of patients in the TID16W, TID28W, TID40W, BID28W, and TID28W-NR 
groups, respectively. Corresponding rates of total bilirubin levels that were higher than 2.6 times the upper limit of the normal range (grade 3 or 4 
hyperbilirubinemia) were 46%, 32%, 33%, 39%, and 13% (these rates are summarized in Table S5 in the Supplementary Appendix).
¶ This category includes all terms associated with rash.
‖ This category includes all terms associated with photosensitivity. Photosensitivity reactions were reported as exaggerated sunburns in sun-
exposed areas and were preventable with sunscreen.
** Asthenia was defined as a loss or lack of bodily strength.
†† Listed are moderate adverse events that occurred in at least 10% of patients in any treatment group during the treatment period.
‡‡ Listed are severe adverse events that occurred in at least two patients.
§§ The four patients who discontinued the study drugs because of jaundice had unconjugated hyperbilirubinemia (conjugated:total bilirubin 
<0.5 in all patients) without concomitant increases in the alanine aminotransferase or aspartate aminotransferase levels from baseline.
¶¶ No cases of life-threatening rashes or serious cutaneous reactions, such as the Stevens–Johnson syndrome, toxic epidermal necrolysis, or 
drug reaction with eosinophilia and systemic symptoms, were reported.
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Discussion
The rates of a sustained virologic response 24 
weeks after the completion of therapy among pa-
tients with previously untreated chronic HCV 
genotype 1 infection who received the current 
standard of care (pegylated interferon, ribavirin, 
and telaprevir or boceprevir) ranged from 68 to 
75% in phase 3 trials.18-22 In this phase 2b study 
involving patients who had not previously re-
ceived treatment for HCV genotype 1 infection, 
the combination of faldaprevir, deleobuvir, and 
ribavirin resulted in rates of a sustained virologic 
response of 52 to 69% 12 weeks after the comple-
tion of therapy.
Overall response rates were not affected by 
the treatment duration. However, the rate of re-
lapse among patients with HCV genotype 1a 
infection who were treated for 16 weeks was 
higher than the rates among patients treated for 
28 or 40 weeks with the same regimen (41% vs. 
0% and 6%). Relapse rates among patients with 
genotype 1b infection were consistently low among 
all treatment groups (0 to 6%); these findings sug-
gest that 16 weeks of treatment may be sufficient 
for this population.
The difference in response rates according to 
the deleobuvir dosage was not significant in this 
study (69% in the BID28W group vs. 59% in the 
TID28W group, P = 0.15). However, the rate of 
premature discontinuation among patients who 
did not have a sustained virologic response 
12 weeks after the completion of therapy was 
higher in the TID28W group than in the BID28W 
group (15% vs. 4%).
The low response rate observed in the group 
of patients who did not receive ribavirin was as-
sociated with high rates of virologic break-
through and relapse. This finding is consistent 
with results from other studies of interferon-free 
regimens without ribavirin.13,17
The higher rate of a sustained virologic re-
sponse 12 weeks after the completion of therapy 
among patients infected with HCV genotype 1b 
than among those infected with genotype 1a 
may be due to the fact that deleobuvir is less ac-
tive against genotype 1a.23,24 In addition, there 
may be a lower barrier to the emergence of re-
Table 4. Changes in Laboratory Values and Other Therapies during the Treatment Period.*
Variable
TID16W 
(N = 81)
TID28W 
(N = 80)
TID40W 
(N = 77)
BID28W 
(N = 78)
TID28W-NR 
(N = 46)
Change in laboratory value from baseline
Alanine aminotransferase — IU/liter –46±35 –48±47 –48±48 –56±62 –43±50
Bilirubin — mg/dl
Total 1.05±1.05 0.98±1.16 0.71±1.12 1.05±1.11 0.46±0.56
Unconjugated 0.53±0.57 0.50±0.68 0.36±0.62 0.56±0.64 0.24±0.31
Hemoglobin — g/dl† –2.5±1.6 –2.6±1.4 –2.5±1.4 –2.6±1.7 –1.0±0.9
Platelet count — ×10−9/liter 54±40 44±57 58±47 36±51 21±39
White-cell count — ×10−9/liter –0.3±1.9 0.2±1.8 0.3±2.1 –0.3±1.5 0.4±1.9
Lowest hemoglobin during treatment — no. (%)
<10.0 g/dl 4 (5) 7 (9) 9 (12) 12 (15) 0
9.0–9.9 g/dl 4 (5) 5 (6) 6 (8) 10 (13) 0
7.0–8.9 g/dl 0 2 (2) 3 (4) 1 (1) 0
<7.0 g/dl 0 0 0 1 (1) 0
Changes in therapy — no. (%)
Ribavirin dose reduction‡ 2 (2) 6 (8) 3 (4) 7 (9) NA
Transfusion 0 0 1 (1) 0 0
Erythropoietin use 0 1 (1) 4 (5) 4 (5) 0
* Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. NA denotes not applicable.
† Anemia was reported as an adverse event in 1%, 13%, 13%, 10%, and 0% of patients in the TID16W, TID28W, TID40W, TID28W, and 
TID28W-NR groups, respectively.
‡ The dose reduction was due to adverse events or laboratory abnormalities.║
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sistant variants for genotype 1a virus.25 Similar 
results were observed with other interferon-free 
regimens, indicating that genotype 1a may be 
more difficult to treat than genotype 1b.26,27
The observation that the IL28B polymorphism 
(rs12879860) affected the rate of a sustained vi-
rologic response 12 weeks after the completion 
of therapy suggests that innate immunity may 
still be important in interferon-free regimens. 
However, the effect of the IL28B genotype is un-
clear in other interferon-free regimens.11,28
Adverse events were common; overall, 94% of 
patients had adverse events, and 9% had severe 
adverse events. Gastrointestinal and dermato-
logic adverse events were the most frequently 
reported events in this study. Patients received 
loading doses of faldaprevir and deleobuvir on 
the first day of the study to ensure sufficient 
plasma levels of both drugs during the first days 
of treatment. These loading doses may have 
contributed to the higher frequency of gastroin-
testinal events during the first week of treatment 
than later in the treatment period. Jaundice due 
to increased levels of bilirubin from baseline 
levels was observed in this study. Faldaprevir 
inhibits bilirubin metabolism primarily through 
inhibition of UGT1A1,29 which can lead to in-
creased plasma levels of unconjugated bilirubin. 
In all cases of grade 3 or 4 hyperbilirubinemia, 
no concurrent increase in the alanine amino-
transferase level was observed. The lower rate of 
jaundice in the TID28W-NR group (4%) than in 
the other groups can be explained by the ab-
sence of hemolysis in a ribavirin-free treatment.
Substantial reductions in red-cell, white-cell, 
and platelet counts are the most prohibitive side 
effects of interferon-based treatments for HCV 
infection. In the Individualized Dosing Efficacy 
vs. Flat Dosing to Assess Optimal Pegylated In-
terferon Therapy (IDEAL) study,30 30% of pa-
tients treated with pegylated interferon alfa-2a 
and the same dose of ribavirin used in this study 
had hemoglobin levels of less than 10 g per 
deciliter (i.e., anemia). In this study, 10% of pa-
tients in the groups that received ribavirin had 
hemoglobin levels that were less than 10 g per 
deciliter. The lower rate of anemia in this study 
might be due to the absence of the myelosup-
pressive effects of pegylated interferon; however, 
without a comparative study, this observation 
should be interpreted with caution. The low rate 
of anemia and the absence of a detrimental ef-
fect of the interferon-free regimens on white-cell 
or platelet counts may be an advantage of these 
regimens over interferon-based therapy.
This study has some limitations. First, the 
open-label design may have biased the compara-
tive evaluation of the duration of treatment, 
since the patients who received longer regimens 
may have been more prone to early discontinua-
tion of treatment than the patients who received 
shorter regimens. This may have contributed to 
the higher rate of discontinuation in the TID40W 
group. Furthermore, the lack of an interferon-
based control group limits the interpretation of 
the results in relation to the current standard-of-
care treatment.
In conclusion, the interferon-free combina-
tion of faldaprevir and deleobuvir with ribavirin 
for the treatment of HCV genotype 1 infection 
was effective. The presence of ribavirin was 
found to be a necessary component of these 
regimens. The BID28W regimen had a more fa-
vorable efficacy and safety profile than did the 
other regimens examined in this study. The HCV 
genotype 1 subtype and host factors were found 
to be significantly associated with a sustained 
virologic response 12 weeks after the completion 
of therapy.
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